Caveolin-1 mutations in human breast cancer

Functional association with estrogen receptor α-positive status

Tianhong Li, Federica Sotgia, Magalis A. Vuolo, Maomi Li, Wan Cai Yang, Richard G. Pestell, Joseph A. Sparano, Michael P. Lisanti

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

A Japanese study reported that up to 16% of breast cancer samples harbor a sporadic mutation within the human Cav-1 gene, namely P132L. To date, however, no studies have examined the United States' population. Here, we developed a novel allele-specific real-time PCR assay to detect the Cav-1 P132L mutation in mammary tumor cells isolated by laser capture microdissection from formalin-fixed paraffin-embedded breast cancer samples. We report that the Cav-1 P132L mutation is present in ∼19% of estrogen receptor α (ERα)-positive breast cancers but not in ERα-negative breast cancers. This is the first demonstration that the P132L mutation is exclusively associated with ERα-positive mammary tumors. We also identified six novel Cav-1 mutations associated with ERα-positive breast cancers (W128Stop, Y118H, S136R, I141T, Y148H, and Y148S). Thus, the overall incidence of Cav-1 mutations in ERα-positive breast cancers approaches 35% (greater than one-third). To mechanistically dissect the functional relationship between Cav-1 gene inactivation and ERα expression, we isolated primary mammary epithelial cells from wild-type and Cav-1-/- mice and cultured them in a three-dimensional system, allowing them to form mammary acinar-like structures. Under conditions of growth factor deprivation, Cav-1-deficient mammary acini displayed increased ERα levels and enhanced sensitivity toward estrogen-stimulated growth, with specific up-regulation of cyclin D1. Finally, we discuss the possibility that sporadic Cav-1 mutations may act as an initiating event in human breast cancer pathogenesis.

Original languageEnglish (US)
Pages (from-to)1998-2013
Number of pages16
JournalAmerican Journal of Pathology
Volume168
Issue number6
DOIs
StatePublished - Jun 2006

Fingerprint

Caveolin 1
Estrogen Receptors
Breast Neoplasms
Mutation
Breast
Laser Capture Microdissection
Cyclin D1
Gene Silencing
Paraffin
Formaldehyde
Real-Time Polymerase Chain Reaction
Intercellular Signaling Peptides and Proteins
Estrogens
Up-Regulation
Epithelial Cells
Alleles

ASJC Scopus subject areas

  • Pathology and Forensic Medicine

Cite this

Li, T., Sotgia, F., Vuolo, M. A., Li, M., Yang, W. C., Pestell, R. G., ... Lisanti, M. P. (2006). Caveolin-1 mutations in human breast cancer: Functional association with estrogen receptor α-positive status. American Journal of Pathology, 168(6), 1998-2013. https://doi.org/10.2353/ajpath.2006.051089

Caveolin-1 mutations in human breast cancer : Functional association with estrogen receptor α-positive status. / Li, Tianhong; Sotgia, Federica; Vuolo, Magalis A.; Li, Maomi; Yang, Wan Cai; Pestell, Richard G.; Sparano, Joseph A.; Lisanti, Michael P.

In: American Journal of Pathology, Vol. 168, No. 6, 06.2006, p. 1998-2013.

Research output: Contribution to journalArticle

Li, Tianhong ; Sotgia, Federica ; Vuolo, Magalis A. ; Li, Maomi ; Yang, Wan Cai ; Pestell, Richard G. ; Sparano, Joseph A. ; Lisanti, Michael P. / Caveolin-1 mutations in human breast cancer : Functional association with estrogen receptor α-positive status. In: American Journal of Pathology. 2006 ; Vol. 168, No. 6. pp. 1998-2013.
@article{7091ebe199cf48d3a1406515a0f660f3,
title = "Caveolin-1 mutations in human breast cancer: Functional association with estrogen receptor α-positive status",
abstract = "A Japanese study reported that up to 16{\%} of breast cancer samples harbor a sporadic mutation within the human Cav-1 gene, namely P132L. To date, however, no studies have examined the United States' population. Here, we developed a novel allele-specific real-time PCR assay to detect the Cav-1 P132L mutation in mammary tumor cells isolated by laser capture microdissection from formalin-fixed paraffin-embedded breast cancer samples. We report that the Cav-1 P132L mutation is present in ∼19{\%} of estrogen receptor α (ERα)-positive breast cancers but not in ERα-negative breast cancers. This is the first demonstration that the P132L mutation is exclusively associated with ERα-positive mammary tumors. We also identified six novel Cav-1 mutations associated with ERα-positive breast cancers (W128Stop, Y118H, S136R, I141T, Y148H, and Y148S). Thus, the overall incidence of Cav-1 mutations in ERα-positive breast cancers approaches 35{\%} (greater than one-third). To mechanistically dissect the functional relationship between Cav-1 gene inactivation and ERα expression, we isolated primary mammary epithelial cells from wild-type and Cav-1-/- mice and cultured them in a three-dimensional system, allowing them to form mammary acinar-like structures. Under conditions of growth factor deprivation, Cav-1-deficient mammary acini displayed increased ERα levels and enhanced sensitivity toward estrogen-stimulated growth, with specific up-regulation of cyclin D1. Finally, we discuss the possibility that sporadic Cav-1 mutations may act as an initiating event in human breast cancer pathogenesis.",
author = "Tianhong Li and Federica Sotgia and Vuolo, {Magalis A.} and Maomi Li and Yang, {Wan Cai} and Pestell, {Richard G.} and Sparano, {Joseph A.} and Lisanti, {Michael P.}",
year = "2006",
month = "6",
doi = "10.2353/ajpath.2006.051089",
language = "English (US)",
volume = "168",
pages = "1998--2013",
journal = "American Journal of Pathology",
issn = "0002-9440",
publisher = "Elsevier Inc.",
number = "6",

}

TY - JOUR

T1 - Caveolin-1 mutations in human breast cancer

T2 - Functional association with estrogen receptor α-positive status

AU - Li, Tianhong

AU - Sotgia, Federica

AU - Vuolo, Magalis A.

AU - Li, Maomi

AU - Yang, Wan Cai

AU - Pestell, Richard G.

AU - Sparano, Joseph A.

AU - Lisanti, Michael P.

PY - 2006/6

Y1 - 2006/6

N2 - A Japanese study reported that up to 16% of breast cancer samples harbor a sporadic mutation within the human Cav-1 gene, namely P132L. To date, however, no studies have examined the United States' population. Here, we developed a novel allele-specific real-time PCR assay to detect the Cav-1 P132L mutation in mammary tumor cells isolated by laser capture microdissection from formalin-fixed paraffin-embedded breast cancer samples. We report that the Cav-1 P132L mutation is present in ∼19% of estrogen receptor α (ERα)-positive breast cancers but not in ERα-negative breast cancers. This is the first demonstration that the P132L mutation is exclusively associated with ERα-positive mammary tumors. We also identified six novel Cav-1 mutations associated with ERα-positive breast cancers (W128Stop, Y118H, S136R, I141T, Y148H, and Y148S). Thus, the overall incidence of Cav-1 mutations in ERα-positive breast cancers approaches 35% (greater than one-third). To mechanistically dissect the functional relationship between Cav-1 gene inactivation and ERα expression, we isolated primary mammary epithelial cells from wild-type and Cav-1-/- mice and cultured them in a three-dimensional system, allowing them to form mammary acinar-like structures. Under conditions of growth factor deprivation, Cav-1-deficient mammary acini displayed increased ERα levels and enhanced sensitivity toward estrogen-stimulated growth, with specific up-regulation of cyclin D1. Finally, we discuss the possibility that sporadic Cav-1 mutations may act as an initiating event in human breast cancer pathogenesis.

AB - A Japanese study reported that up to 16% of breast cancer samples harbor a sporadic mutation within the human Cav-1 gene, namely P132L. To date, however, no studies have examined the United States' population. Here, we developed a novel allele-specific real-time PCR assay to detect the Cav-1 P132L mutation in mammary tumor cells isolated by laser capture microdissection from formalin-fixed paraffin-embedded breast cancer samples. We report that the Cav-1 P132L mutation is present in ∼19% of estrogen receptor α (ERα)-positive breast cancers but not in ERα-negative breast cancers. This is the first demonstration that the P132L mutation is exclusively associated with ERα-positive mammary tumors. We also identified six novel Cav-1 mutations associated with ERα-positive breast cancers (W128Stop, Y118H, S136R, I141T, Y148H, and Y148S). Thus, the overall incidence of Cav-1 mutations in ERα-positive breast cancers approaches 35% (greater than one-third). To mechanistically dissect the functional relationship between Cav-1 gene inactivation and ERα expression, we isolated primary mammary epithelial cells from wild-type and Cav-1-/- mice and cultured them in a three-dimensional system, allowing them to form mammary acinar-like structures. Under conditions of growth factor deprivation, Cav-1-deficient mammary acini displayed increased ERα levels and enhanced sensitivity toward estrogen-stimulated growth, with specific up-regulation of cyclin D1. Finally, we discuss the possibility that sporadic Cav-1 mutations may act as an initiating event in human breast cancer pathogenesis.

UR - http://www.scopus.com/inward/record.url?scp=33744776333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33744776333&partnerID=8YFLogxK

U2 - 10.2353/ajpath.2006.051089

DO - 10.2353/ajpath.2006.051089

M3 - Article

VL - 168

SP - 1998

EP - 2013

JO - American Journal of Pathology

JF - American Journal of Pathology

SN - 0002-9440

IS - 6

ER -